From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...
Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
8d
GlobalData on MSNAstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
News Medical on MSN17d
Artificial intelligence model identifies potential risk genes for Parkinson’s diseaseResearchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics models to Parkinson’s disease. Researchers identified genetic factors in ...
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
The proteins were gathered from cerebrospinal ... Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12, 2024 — Researchers have identified a potential biomarker ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results